AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com

AC Immune (NASDAQ:ACIU - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of AC Immune in a research report on Friday, March 15th.

AC Immune Stock Down 1.3 %

NASDAQ:ACIU traded down $0.03 during midday trading on Wednesday, hitting $2.35. The company had a trading volume of 138,032 shares, compared to its average volume of 169,790. AC Immune has a 52-week low of $1.90 and a 52-week high of $5.14. The stock's fifty day moving average price is $2.92 and its 200-day moving average price is $3.32. The company has a market capitalization of $232.42 million, a PE ratio of -3.31 and a beta of 1.05.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million during the quarter, compared to analysts' expectations of $16.36 million. As a group, research analysts forecast that AC Immune will post -0.74 earnings per share for the current year.

Institutional Trading of AC Immune

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in AC Immune in the fourth quarter worth $48,000. Avidity Partners Management LP raised its stake in shares of AC Immune by 2.3% during the third quarter. Avidity Partners Management LP now owns 2,969,800 shares of the company's stock valued at $8,464,000 after acquiring an additional 66,522 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock valued at $33,000 after acquiring an additional 8,423 shares during the last quarter. BVF Inc. IL raised its stake in shares of AC Immune by 96.2% during the fourth quarter. BVF Inc. IL now owns 14,571,236 shares of the company's stock valued at $72,856,000 after acquiring an additional 7,142,857 shares during the last quarter. Finally, Platinum Investment Management Ltd. raised its stake in shares of AC Immune by 14.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company's stock valued at $7,578,000 after acquiring an additional 193,123 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.